ERG and prostate cancer: To evaluate whether BCAR1 expression is associated with ERG rearrangements in prostate cancers, we used pre-existing data on ERG status obtained by FISH in 5379 cancers and by IHC in 8421 tumors for which BCAR1 staining was also available.